Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.

Autor: Sinner F; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany., Pinter M; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, A-1090 Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, A-1090 Vienna, Austria., Scheiner B; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, A-1090 Vienna, Austria.; Liver Cancer (HCC) Study Group Vienna, Medical University of Vienna, A-1090 Vienna, Austria., Ettrich TJ; Ulm University Hospital, Department of Internal Medicine I, 89081 Ulm, Germany., Sturm N; Ulm University Hospital, Department of Internal Medicine I, 89081 Ulm, Germany., Gonzalez-Carmona MA; Department of Internal Medicine I, University Hospital of Bonn, 53127 Bonn, Germany., Waidmann O; Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany.; University Cancer Center Frankfurt, University Hospital Frankfurt, 60590 Frankfurt, Germany.; Center for Hematology and Oncology Bethanien, 60389 Frankfurt, Germany., Finkelmeier F; Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany.; University Cancer Center Frankfurt, University Hospital Frankfurt, 60590 Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University Frankfurt/Main, 60590 Frankfurt, Germany., Himmelsbach V; Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, 60590 Frankfurt, Germany., De Toni EN; Department of Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany., Ben Khaled N; Department of Medicine II, University Hospital, LMU Munich, 81377 Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center, 69120 Heidelberg, Germany., Mohr R; Department of Hepatology & Gastroenterology, Campus Virchow Klinikum and Campus Charité Mitte, Charité University Medicine Berlin, 10117 Berlin, Germany., Fründt TW; Department of Internal Medicine, Gastroenterology & Hepatology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Kütting F; Clinic for Gastroenterology and Hepatology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany., Bömmel FV; Department of Medicine II, Division of Hepatology, Leipzig University Medical Center, 04103 Leipzig, Germany., Lieb S; Department of Medicine II, Division of Hepatology, Leipzig University Medical Center, 04103 Leipzig, Germany., Krug S; Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, 06120 Halle, Germany., Bettinger D; Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Schultheiß M; Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany., Jochheim LS; Department of Gastroenterology and Hepatology, University Hospital Essen, 45147 Essen, Germany., Best J; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.; Department of Internal Medicine, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, 44892 Bochum, Germany., Müller C; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany., Keitel V; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany., Venerito M; Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 Dec 02; Vol. 14 (23). Date of Electronic Publication: 2022 Dec 02.
DOI: 10.3390/cancers14235966
Abstrakt: Atezolizumab plus bevacizumab is the standard of care for first-line systemic therapy for advanced hepatocellular carcinoma (aHCC). Data on the efficacy and safety of atezolizumab plus bevacizumab in patients with aHCC who have received prior systemic therapy are not available. Methods: Patients with aHCC who received atezolizumab plus bevacizumab after at least one systemic treatment between December 2018 and March 2022 were retrospectively identified in 13 centers in Germany and Austria. Patient characteristics, tumor response rates, progression-free survival (PFS), overall survival (OS), and adverse events (AE) were analyzed. Results: A total of 50 patients were identified; 41 (82%) were male. The median age at initiation of treatment with atezolizumab plus bevacizumab was 65 years, 41 (82%) patients had cirrhosis, 30 (73%) Child A, 9 (22%) B, and 2 (5%) C. A total of 34 patients (68%) received atezolizumab plus bevacizumab in the second-line setting and 16 (32%) in later lines. The best radiologic tumor responses were complete remission (2%), partial remission (30%), stable disease (36%), and progressive disease (18%), resulting in an objective response rate of 32% and a disease control rate of 68%. Median OS was 16.0 months (95% confidence interval 5.6-26.4 months), and median PFS was 7.1 months (95% confidence interval 4.4-9.8 months). AE grades 3-4 were observed in seven (14%) and resulted in death in three patients (6%). There were five (10%) bleeding events with a grade ≥ 3, including one (2%) with a fatal outcome. Conclusions: Atezolizumab plus bevacizumab is effective in patients with aHCC who did not have access to this option as first-line therapy. The safety profile was consistent with previous reports.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje